<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Immunotherapy advancements &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/immunotherapy-advancements/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 14 Jan 2026 16:51:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Immunotherapy advancements &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Harnessing CAR T-Cells for Chronic Viral Infections</title>
		<link>https://bioengineer.org/harnessing-car-t-cells-for-chronic-viral-infections/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 14 Jan 2026 16:51:23 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[chronic viral infections]]></category>
		<category><![CDATA[immune evasion]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[translational medicine]]></category>
		<guid isPermaLink="false">https://bioengineer.org/harnessing-car-t-cells-for-chronic-viral-infections/</guid>

					<description><![CDATA[Chimeric Antigen Receptor T-Cell Therapy: A Revolutionary Approach to Chronic Viral Infections Chronic viral infections pose significant challenges to global health, affecting millions of individuals worldwide. Despite advancements in antiviral therapies, many patients experience persistent viral replication and chronic disease due to the virus’s ability to evade the immune system. In recent years, immunotherapy, and [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">316887</post-id>	</item>
		<item>
		<title>Revolutionizing AML: CAR-T and CAR-NK Cell Therapies</title>
		<link>https://bioengineer.org/revolutionizing-aml-car-t-and-car-nk-cell-therapies/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 25 Oct 2025 21:22:17 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Acute myeloid leukemia (AML)]]></category>
		<category><![CDATA[CAR-NK cell therapy]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[tumor microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revolutionizing-aml-car-t-and-car-nk-cell-therapies/</guid>

					<description><![CDATA[In recent years, the application of immunotherapy in the treatment of acute myeloid leukemia (AML) has garnered increasing attention within the scientific community. Among the most promising advancements in this realm are the development and application of Chimeric Antigen Receptor T-cell (CAR-T) and Natural Killer (NK) cell therapies. A recent study led by researchers Wu, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">286884</post-id>	</item>
		<item>
		<title>Revolutionizing Immunotherapy: Mass Production of CAR-iNK Cells</title>
		<link>https://bioengineer.org/revolutionizing-immunotherapy-mass-production-of-car-ink-cells/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 11 Oct 2025 09:41:58 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[adoptive cell transfer engineering]]></category>
		<category><![CDATA[Cancer treatment innovation]]></category>
		<category><![CDATA[CAR-NK cell mass production]]></category>
		<category><![CDATA[CD34+ HSPC-derived therapies]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revolutionizing-immunotherapy-mass-production-of-car-ink-cells/</guid>

					<description><![CDATA[Chimaeric antigen receptor (CAR) natural killer (CAR-NK) cells signify a revolutionary stride in the realm of immunotherapy, presenting a compelling alternative to the traditionally employed CAR-T cells. Their application is underscored by the urgent requirement for effective cancer treatments, leading researchers to explore innovative methodologies for generating robust immune responses capable of combating malignancies. One [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">279107</post-id>	</item>
		<item>
		<title>CAR T-Cell and TIL Therapies in GI Cancers</title>
		<link>https://bioengineer.org/car-t-cell-and-til-therapies-in-gi-cancers/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sat, 20 Sep 2025 07:34:18 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[Clinical oncology research]]></category>
		<category><![CDATA[Gastrointestinal malignancies]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[Tumor-infiltrating lymphocytes (TILs)]]></category>
		<guid isPermaLink="false">https://bioengineer.org/car-t-cell-and-til-therapies-in-gi-cancers/</guid>

					<description><![CDATA[In the relentless battle against gastrointestinal malignancies, immunotherapy has emerged as a beacon of hope, transforming once grim prognoses into stories of resilience and recovery. Among the most promising advances are the therapies involving chimeric antigen receptor T-cells (CAR T-cells) and tumor-infiltrating lymphocytes (TILs). A newly published comprehensive review by Sayed et al. in Medical [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">270905</post-id>	</item>
		<item>
		<title>Bystander T Cells Boost the Antitumor Efficacy of Bispecific Antibodies</title>
		<link>https://bioengineer.org/bystander-t-cells-boost-the-antitumor-efficacy-of-bispecific-antibodies/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 07 Aug 2025 21:38:21 +0000</pubDate>
				<category><![CDATA[Technology]]></category>
		<category><![CDATA[B-cell lymphomas]]></category>
		<category><![CDATA[bispecific antibodies]]></category>
		<category><![CDATA[bystander T-cells]]></category>
		<category><![CDATA[CAR-T therapy]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/bystander-t-cells-boost-the-antitumor-efficacy-of-bispecific-antibodies/</guid>

					<description><![CDATA[Researchers are continuing to make strides in the field of immunotherapy, particularly focusing on the treatment of relapsed or refractory B-cell lymphomas. Among the innovative approaches, the combination of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) has emerged as a promising strategy, showing potential for enhanced efficacy in therapeutic outcomes. This integrated [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">254531</post-id>	</item>
		<item>
		<title>CAR T-Cell Therapy: The Future of Cancer Eradication</title>
		<link>https://bioengineer.org/car-t-cell-therapy-the-future-of-cancer-eradication/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 06 Aug 2025 20:38:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Cancer Treatment Innovations]]></category>
		<category><![CDATA[CAR-T cell therapy]]></category>
		<category><![CDATA[Genetic Engineering in Medicine]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[precision oncology]]></category>
		<guid isPermaLink="false">https://bioengineer.org/car-t-cell-therapy-the-future-of-cancer-eradication/</guid>

					<description><![CDATA[In recent years, the revolutionary field of immunotherapy has drastically reshaped the landscape of cancer treatment, pushing the boundaries of what modern medicine can achieve. Among these advancements, Chimeric Antigen Receptor (CAR) T-cell therapy stands out as one of the most promising strategies that could redefine the future of cancer eradication. Building upon decades of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">254096</post-id>	</item>
		<item>
		<title>Penn Medicine Showcases Groundbreaking Research at AACR Annual Meeting 2025</title>
		<link>https://bioengineer.org/penn-medicine-showcases-groundbreaking-research-at-aacr-annual-meeting-2025/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 21 Apr 2025 17:55:15 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AACR Annual Meeting 2025]]></category>
		<category><![CDATA[Cancer metabolism research]]></category>
		<category><![CDATA[Epigenetic cancer therapies]]></category>
		<category><![CDATA[Immunotherapy advancements]]></category>
		<category><![CDATA[Penn Medicine oncology innovations]]></category>
		<guid isPermaLink="false">https://bioengineer.org/penn-medicine-showcases-groundbreaking-research-at-aacr-annual-meeting-2025/</guid>

					<description><![CDATA[PHILADELPHIA – As the American Association for Cancer Research (AACR) Annual Meeting 2025 convenes in Chicago from April 25 to 30, researchers from the University of Pennsylvania’s Abramson Cancer Center (ACC) and the Perelman School of Medicine are poised to unveil pivotal insights that promise to reshape the landscape of cancer biology and therapeutic approaches. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">241634</post-id>	</item>
	</channel>
</rss>
